Key result
This review evaluates the literature regarding the incidence and cross-reactivity of angioedema associated with ACE inhibitors and ARBs to provide guidance for clinical decision making.
This review summarizes the incidence and cross-reactivity of angioedema associated with ACEIs and ARBs to guide clinical decision-making.
May support cautious ARB use after ACEI angioedema; leaves open precise cross-reactivity estimates from prospective trials.
Angiotensin inhibitors have been extensively evaluated in clinical trials and have demonstrated significant reductions in morbidity and mortality following myocardial infarction and stroke, as well as in patients with heart failure or who are at risk of cardiovascular disease. Further, both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are frequently prescribed for the treatment of hypertension and to preserve renal function in patients with diabetes mellitus and chronic kidney disease. Angioedema is a known, but rare, adverse effect of ACEIs and ARBs. Therefore, it is important for clinicians to have a thorough understanding of risks and benefits of prescribing these medications, particularly in patients with a history of angioedema. This review describes the literature evaluating the incidence and cross-reactivity of angioedema with ACEIs and ARBs in order to provide guidance for clinical decision making.
No takes yet. Share an insight, caveat, or question.
Knecht et al. (2014) conducted a review in Angioedema. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) was evaluated on Incidence and cross-reactivity of angioedema. This review evaluates the literature regarding the incidence and cross-reactivity of angioedema associated with ACE inhibitors and ARBs to provide guidance for clinical decision making.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: